Literature DB >> 3375279

Validation of the exchange assay for the measurement of androgen receptors in human and dog prostates.

A M Traish1, D F Williams, N D Hoffman, H H Wotiz.   

Abstract

This study describes an exchange assay for measurement of cytosolic and nuclear androgen receptors (AR) in human and dog prostates. Efficient replacement of endogenously bound ligand from the receptor with [3H] mibolerone was achieved by incubation of cytosolic or nuclear fractions at 0 degree C for 72 h in the presence of 0.15M NaSCN and 15% sucrose. It was demonstrated that in the presence of the chaotropic salt rapid steroid dissociation took place at 0 degree C followed by [3H] mibolerone binding; sucrose protected the AR from denaturation by NaSCN. Combination of these two reagents, therefore, allowed quantitative androgen exchange at 0 degrees C. Receptors determined by this exchange procedure are specific for androgens, of high affinity (KD 2-5 nM), and sedimented on sucrose gradients as 4-4.6S entities. Use of [3H] mibolerone minimized interference from plasma proteins and reduced nonspecific binding. This exchange assay has now been applied to quantitation of cytosolic and nuclear AR in small tissue samples (50 mg). Thus it is possible to measure AR in tissue samples obtained by needle biopsies and attempt to correlate receptor values to clinical response of prostatic cancer patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3375279

Source DB:  PubMed          Journal:  Prog Clin Biol Res        ISSN: 0361-7742


  9 in total

Review 1.  Testosterone therapy and prostate cancer--safety concerns are well founded.

Authors:  Laurence Klotz
Journal:  Nat Rev Urol       Date:  2015-01       Impact factor: 14.432

Review 2.  Testosterone Therapy in Men With Prostate Cancer.

Authors:  Alan L Kaplan; Jim C Hu; Abraham Morgentaler; John P Mulhall; Claude C Schulman; Francesco Montorsi
Journal:  Eur Urol       Date:  2015-12-21       Impact factor: 20.096

3.  Androgen replacement therapy after prostate cancer treatment.

Authors:  Mohit Khera
Journal:  Curr Urol Rep       Date:  2010-11       Impact factor: 3.092

4.  Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage.

Authors:  Payel Chatterjee; Michael T Schweizer; Jared M Lucas; Ilsa Coleman; Michael D Nyquist; Sander B Frank; Robin Tharakan; Elahe Mostaghel; Jun Luo; Colin C Pritchard; Hung-Ming Lam; Eva Corey; Emmanuel S Antonarakis; Samuel R Denmeade; Peter S Nelson
Journal:  J Clin Invest       Date:  2019-07-16       Impact factor: 14.808

Review 5.  Testosterone therapy in men with prostate cancer: literature review, clinical experience, and recommendations.

Authors:  Abraham Morgentaler; William P Conners
Journal:  Asian J Androl       Date:  2015 Mar-Apr       Impact factor: 3.285

Review 6.  Serum testosterone level, testosterone replacement treatment, and prostate cancer.

Authors:  Ali Atan; Altug Tuncel; Suleyman Yesil; Derya Balbay
Journal:  Adv Urol       Date:  2013-09-18

7.  Do we have enough evidences that make you safe to treat a man with hypogonadism one year after a radical prostatectomy for prostate cancer? | Opinion: Not Yet.

Authors:  Marcelo Langer Wroclawski; Flavio Lobo Heldwein
Journal:  Int Braz J Urol       Date:  2018 Jan-Feb       Impact factor: 1.541

Review 8.  Shifting the Paradigm of Testosterone Replacement Therapy in Prostate Cancer.

Authors:  Michael A Bell; Jeffrey D Campbell; Gregory Joice; Nikolai A Sopko; Arthur L Burnett
Journal:  World J Mens Health       Date:  2018-03-22       Impact factor: 5.400

Review 9.  The effects of testosterone replacement therapy on the prostate: a clinical perspective.

Authors:  Saiful Miah; Tharu Tharakan; Kylie A Gallagher; Taimur T Shah; Mathias Winkler; Channa N Jayasena; Hashim U Ahmed; Suks Minhas
Journal:  F1000Res       Date:  2019-02-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.